What this means
Doctors want to learn what leads to frailty and serious side effects in men over 65 getting hormone therapy. The study is still recruiting, so no results are available yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 Minutes and over
- Where
- 1 site, including Illinois
The science
- Registered title
- Geriatric Assessment and Technology Evaluation in Prostate Cancer
- Trial ID
- NCT06215508 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic
- What is tested
- Questionnaires
- Sponsor
- University of Chicago
- Ages
- 18 Minutes to no maximum
- Dates
- First posted Jan 22, 2024 · updated Jun 8, 2025
Registry summary
By doing this study, doctors hope to learn more about factors that contribute to frailty (a condition where older adults feel weak, get tired easily, and struggle more with everyday activities) and serious side effects among men over the age of 65 who will receive androgen deprivation therapy (also called "hormone therapy") for prostate cancer that has spread to other parts of their body. Participation in this research will last about 5 years. For the first year, participants will have 5 study visits where they have give blood samples, answer survey questions, and use a wearable device. After study visits are complete, there is a 4-year follow-up period. Research team will check regular doctor visits and look at participants' medical records.
Sites (1)
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States